Author

Larissa Kopp

Observed name: Kopp, L.

Institution: Paul Ehrlich Institut

Observed institutions: Fraunhofer Institute for Translational Medicine and Pharmacology, LOEWE Centre for Translational Biodiversity Genomics, Paul Ehrlich Institut

OpenAlex ID: A5010242863

Xenocoumacin 2 reduces protein biosynthesis and inhibits inflammatory and angiogenesis-related processes in endothelial cells

2021 · Pelin Erkoc, Michaela Schmitt, et al. · Biomedicine & Pharmacotherapy · 5

Mobile-app-based cohort event monitoring study (CEM) of COVID-19 vaccines

2026 · Larissa Kopp, Benjamin Hofner, et al. · Vaccine

The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update

2026 · Jürgen Beckmann, Marco Tuccori, et al. · Drug Safety

Complementary, descriptive analyses of real-world data on adverse drug reactions associated with the use of checkpoint inhibitors in skin cancer patients

2025 · Dubrall, D., Wittenberg, J., et al. · RWTH Publications (RWTH Aachen)

Works count: 4

Citation count: 5

H-index: 1

I10-index: